Tarsus Pharmaceuticals, Inc. SEC Filings

Tarsus Pharmaceuticals, Inc. furnished a new corporate presentation under Regulation FD. The company posted the presentation on the Investor & News section of its website and attached it as Exhibit 99.1 to this report. The materials are designated as “furnished” rather than “filed,” which means they are not subject to certain liability provisions under the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings unless expressly stated.

Tarsus Pharmaceuticals’ Chief Human Resources Officer, Dianne C. Whitfield, reported automatic stock sales made under a pre-arranged Rule 10b5-1 trading plan. On January 2, 2026, she sold a total of 15,565 shares of Tarsus common stock in four transactions at weighted average prices ranging from about $80.09 to $82.93. The footnotes explain that each reported price is a weighted average for multiple individual trades, with actual prices spanning from $79.42 to $83.32. After these sales, she directly owned 23,393 shares of Tarsus common stock.

Tarsus Pharmaceuticals, Inc. Chief Operating Officer reported stock gifts in an insider filing. On 12/16/2025, he transferred 950 shares of common stock at a stated price of $0, leaving 79,183 shares of common stock held directly, which includes 451 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025.

A separate reported transaction on the same date reflects a gift coded as G(2) involving 475 shares of common stock held indirectly by his daughter. The report notes that he disclaims beneficial ownership of the securities held by his daughter and that this reporting is not an admission of beneficial ownership for Section 16 or any other purpose.

Tarsus Pharmaceuticals, Inc. disclosed that its Chief Human Resources Officer, an officer of the company, sold common stock in a pre‑planned trade. On 12/16/2025, the officer sold 7,397 shares of Tarsus common stock at a price of $80.1 per share in a transaction coded as a sale. The filing states that this was an automatic sale made under a Rule 10b5‑1 trading plan adopted on September 12, 2025, indicating the trade was scheduled in advance. After this transaction, the officer beneficially owned 38,958 shares of Tarsus common stock, held directly.

Tarsus Pharmaceuticals, Inc. reported insider stock sales by a company director. On December 15, 2025, the reporting person sold several blocks of Tarsus common stock in open-market transactions. Direct holdings were reduced through sales of 5,046 shares at a weighted average price of $80.8, 6,306 shares at $81.75, and 1,148 shares at $82.39, among other trades.

Some of these sales were executed automatically under a Rule 10b5-1 trading plan adopted on September 8, 2025, while others were not made under such a plan. The director also sold shares held indirectly through Link Family Enterprise, LP. After the reported transactions, the reporting person directly owned 128,832 Tarsus shares and no longer held shares indirectly through the partnership.

Tarsus Pharmaceuticals, Inc. Chief Medical Officer reported equity transactions tied to restricted stock units (RSUs). On December 15, 2025, 6,819 RSUs vested and were settled into an equal number of common shares. On December 16, 2025, 2,078 common shares were sold at $79.5 per share to cover tax withholding obligations under a mandated “sell to cover” arrangement, rather than as a discretionary sale.

After these transactions, the officer beneficially owned 24,019 common shares directly, plus 6,360 shares held indirectly through a spouse’s Roth IRA and 12,040 shares held through a 401(k) plan. The officer also held 20,459 RSUs, which each represent a contingent right to receive one share of common stock and vest in four equal annual installments on December 15 of 2025, 2026, 2027, and 2028, subject to continuous service.

Tarsus Pharmaceuticals President and CEO Bobak Azamian, who is also Board Chair and a director, reported a transfer of 51,885 shares of common stock on December 4, 2025. The shares were moved for no consideration to the Bobak Azamian Living Trust, established April 16, 2018.

After the transaction, he holds 1,750 Tarsus shares directly and 863,991 shares indirectly through the trust, where he serves as trustee with voting and dispositive power over these shares. The report reflects a restructuring of how his holdings are owned rather than a cash sale.

Tarsus Pharmaceuticals reported Q3 2025 results showing rapid commercial growth of XDEMVY and continued investment in commercialization. Product sales, net were $118.7 million, up from $48.1 million a year ago. The company posted a net loss of $12.6 million, with operating expenses led by selling, general and administrative of $108.6 million, research and development of $16.3 million, and cost of sales of $8.3 million.

For the nine months, product sales, net totaled $299.7 million and the net loss was $58.0 million. Liquidity strengthened: cash and cash equivalents were $112.7 million and marketable securities were $289.1 million as of September 30, 2025. Stockholders’ equity reached $335.1 million, with long‑term debt of $72.3 million. The company completed a March 2025 follow‑on offering for approximately $134.8 million in net proceeds to support operations. Shares outstanding were 42,449,105 as of October 29, 2025.

Tarsus Pharmaceuticals (TARS) filed an 8-K stating it furnished a press release reporting results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.

The information was furnished under Item 2.02 and is not deemed filed for liability purposes under Section 18. The filing was signed by Jeffrey Farrow, Chief Financial Officer and Chief Strategy Officer.